Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Lowe

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Frontiers in Immunology|June 20, 2022
Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation: An Update From the COV-AD StudyAdrian M Shields, Sian E Faustini, Harriet J Hill, et al.
The Journal of Infection|March 25, 2024
Novel antivirals for severe enterovirus infection in immunocompromised hosts; A case seriesAndrea Meinhardt, Liam Reilly, Marios Kaliakatsos, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 20, 2023
Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike ProteinVinit Upasani, Katie Townsend, Mary Y Wu, et al.
British Journal of Haematology|June 12, 2023
Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromesJustin Loke, Vinit Upasani, Charlotte Gaskell, et al.
The Journal of Experimental Medicine|August 4, 2021
Eosinophils are part of the granulocyte response in tuberculosis and promote host resistance in miceAndrea C Bohrer, Ehydel Castro, Zhidong Hu, et al.
The Lancet. Infectious Diseases|September 12, 2024
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trialVictoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, et al.
The New England Journal of Medicine|April 22, 2026
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk OutpatientsChristopher C Butler, Andrew D Pinto, Victoria Harris, et al.
Nature Communications|February 23, 2024
Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatientsJoseph F Standing, Laura Buggiotti, Jose Afonso Guerra-Assuncao, et al.
BMJ Open|August 7, 2023
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe diseaseOghenekome Gbinigie, Emma Ogburn, Julie Allen, et al.
Clinical and Experimental Immunology|May 31, 2022
Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UKAdrian M Shields, Ariharan Anantharachagan, Gururaj Arumugakani, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Frontiers in Immunology|June 20, 2022
Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation: An Update From the COV-AD StudyAdrian M Shields, Sian E Faustini, Harriet J Hill, et al.
The Journal of Infection|March 25, 2024
Novel antivirals for severe enterovirus infection in immunocompromised hosts; A case seriesAndrea Meinhardt, Liam Reilly, Marios Kaliakatsos, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 20, 2023
Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike ProteinVinit Upasani, Katie Townsend, Mary Y Wu, et al.
British Journal of Haematology|June 12, 2023
Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromesJustin Loke, Vinit Upasani, Charlotte Gaskell, et al.
The Journal of Experimental Medicine|August 4, 2021
Eosinophils are part of the granulocyte response in tuberculosis and promote host resistance in miceAndrea C Bohrer, Ehydel Castro, Zhidong Hu, et al.
The Lancet. Infectious Diseases|September 12, 2024
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trialVictoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, et al.
The New England Journal of Medicine|April 22, 2026
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk OutpatientsChristopher C Butler, Andrew D Pinto, Victoria Harris, et al.
Nature Communications|February 23, 2024
Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatientsJoseph F Standing, Laura Buggiotti, Jose Afonso Guerra-Assuncao, et al.
BMJ Open|August 7, 2023
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe diseaseOghenekome Gbinigie, Emma Ogburn, Julie Allen, et al.
Clinical and Experimental Immunology|May 31, 2022
Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UKAdrian M Shields, Ariharan Anantharachagan, Gururaj Arumugakani, et al.
Pageof 10